3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Neoplasm Metastasis
1
Carcinoma, Squamous Cell
1
Interventions
Cisplatin
52
Radiotherapy
43
Cetuximab
30
Fluorouracil
27
pembrolizumab
19
Carboplatin
19
Docetaxel
14
Paclitaxel
8
Radiotherapy, Intensity-Modulated
7
Nivolumab
6
Methotrexate
6
Drug Therapy
6
Surgical Procedures, Operative
5
Chemotherapy, Adjuvant
5
Radiation
4
Neoadjuvant Therapy
4
Magnetic Resonance Spectroscopy
4
nimotuzumab
3
Taxes
3
Chemoradiotherapy
3
toripalimab
2
lenvatinib
2
epacadostat
2
durvalumab
2
dehydroftorafur
2
camrelizumab
2
avelumab
2
advexin
2
Specimen Handling
2
Radiotherapy, Conformal
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Squamous Cell Carcinoma of Head and Neck
×
ficlatuzumab
×
Clear all
NCT06064877
2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3
Recruiting
410 enrolled